MedTrace Logo

Hepa Wash Treatment of Patients With Acute-on-Chronic Liver Failure in Intensive Care Units

NCT01079091 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 14

Last updated 2019-07-05

No results posted yet for this study

Summary

Patients with compensated chronic liver disease who have an episode of acute deterioration of liver function (acute-on-chronic liver failure) are known to have up to 90% mortality rate. Hepa Wash(R) is a newly developed liver and renal support system that is based on the use of recycled albumin dialysate. The new system has shown a high detoxification capacity in in-vitro and preclinical studies. The aim of the study is to evaluate the safety and efficacy of the Hepa Wash system in patients with acute-on-chronic liver failure in the intensive care unit.

Conditions

  • Acute on Chronic Hepatic Failure

Interventions

DEVICE

ADVOS (Hepa Wash)

Intervention frequency: 1-10 treatments (decision of the investigator) Duration of intervention per patient: Treatment until recovery or death (max. 6 weeks)

PROCEDURE

Standard Medical Therapy

Standard of care treatment

Sponsors & Collaborators

  • Hepa Wash GmbH

    lead INDUSTRY

Principal Investigators

  • Wolfgang Huber, PD Dr. · II Medizinische Klinik, Klinikum rechts der Isar, Munich

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2013-07-31
Completion
2013-10-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01079091 on ClinicalTrials.gov